title: Induction of neutralizing antibodies to T-cell line-adapted and primary human immunodeficiency virus type 1 isolates with a prime-boost vaccine regimen in chimpanzees.
abstract: Five chimpanzees were immunized by administration of one or more intranasal priming doses of one to three recombinant adenoviruses containing a gp160 insert from human immunodeficiency virus type 1 (HIV-1) MN (HIV-1MN) followed by one or more boosts of recombinant HIV-1SF2 gp120 delivered intramuscularly with MF59 adjuvant. This regimen resulted in humoral immune responses in three of five animals. Humoral responses included immunochemically active anti-H1V-1 antibodies (Abs) directed to recombinant gp120 and neutralizing Abs reactive with T-cell-line-adapted HIV-1MN and HIV-1SF2. In addition, neutralizing activity was detected to the two homologous primary isolates and to two of three heterologous primary isolates which, like the immunizing strains, can use CXCR4 as a coreceptor for infection. The three animals with detectable neutralizing Abs and a fourth exhibiting the best cytotoxic T-lymphocyte response were protected from a low-dose intravenous challenge with a cell-free HIV-1SF2 primary isolate administered 4 weeks after the last boost. Animals were rested for 46 weeks and then rechallenged, without a boost, with an eightfold-higher challenge dose of HIV-1SF2. The three animals with persistent neutralizing Abs were again protected. These data show that a strong, long-lived protective Ab response can be induced with a prime-boost regimen in chimpanzees. The data suggest that in chimpanzees, the presence of neutralizing Abs correlates with protection for animals challenged intravenously with a high dose of a homologous strain of HIV-1, and they demonstrate for the first time the induction of neutralizing Abs to homologous and heterologous primary isolates.
authors.affiliation: Veterans Affairs Medical Center, New York 10010, USA. Zollas01@mcrcr6.med.nyu.edu
authors.forename: S
authors.initials: S
authors.lastname: Zolla-Pazner
authors.forename: M
authors.initials: M
authors.lastname: Lubeck
authors.forename: S
authors.initials: S
authors.lastname: Xu
authors.forename: S
authors.initials: S
authors.lastname: Burda
authors.forename: R J
authors.initials: RJ
authors.lastname: Natuk
authors.forename: F
authors.initials: F
authors.lastname: Sinangil
authors.forename: K
authors.initials: K
authors.lastname: Steimer
authors.forename: R C
authors.initials: RC
authors.lastname: Gallo
authors.forename: J W
authors.initials: JW
authors.lastname: Eichberg
authors.forename: T
authors.initials: T
authors.lastname: Matthews
authors.forename: M
authors.initials: M
authors.lastname: Robert-Guroff
mesh_terms: D000818:Animals; D000914:Antibodies, Viral / Q000276:immunology*; D000956:Antigens, Viral / Q000276:immunology; D019302:HIV Envelope Protein gp160 / Q000276:immunology*; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D007114:Immunization; D002679:Pan troglodytes; D013601:T-Lymphocytes / Q000276:immunology*; D014765:Viral Vaccines
chemical_list: D000914:Antibodies, Viral; D000956:Antigens, Viral; D019302:HIV Envelope Protein gp160; D014765:Viral Vaccines